Ensifentrine, a novel, selective dual inhibitor of PDE-3 and PDE-4, received FDA approval in 2023 for use in patients with moderate to severe COPD, after phase III trials demonstrated significant improvements in lung function, exacerbation rates, and symptom burden [47]. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.